TS
CYTK icon

Thomas Steyer’s Cytokinetics CYTK Stock Holding History

Thomas Steyer’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-102,400
Closed -$5.41M – 159
2024
Q3 		$5.41M Hold
102,400
– – 0.02% 95
2024
Q2 		$5.55M Hold
102,400
– – 0.02% 91
2024
Q1 		$7.18M Sell
102,400
-985,372
-91% -$76.2M 0.03% 98
2023
Q4 		$90.8M Buy
1,087,772
+1,066,000
+4,896% +$38.6M 0.42% 48
2023
Q3 		$641K Hold
21,772
– – ﹤0.01% 116
2023
Q2 		$710K Sell
21,772
-916,300
-98% -$33.9M ﹤0.01% 127
2023
Q1 		$33M Sell
938,072
-763,666
-45% -$31.2M 0.18% 70
2022
Q4 		$78M Buy
1,701,738
+80,700
+5% +$3.47M 0.46% 53
2022
Q3 		$78.5M Sell
1,621,038
-624,000
-28% -$30M 0.43% 62
2022
Q2 		$88.2M Buy
2,245,038
+362,439
+19% +$14.6M 0.48% 58
2022
Q1 		$69.3M Sell
1,882,599
-287,743
-13% -$10.2M 0.33% 62
2021
Q4 		$98.9M Sell
2,170,342
-562,433
-21% -$21.7M 0.49% 49
2021
Q3 		$97.7M Sell
2,732,775
-143,225
-5% -$4.22M 0.46% 55
2021
Q2 		$56.9M Buy
2,876,000
+376,000
+15% +$8.83M 0.23% 68
2021
Q1 		$58.1M Buy
2,500,000
+100,000
+4% +$2.14M 0.29% 66
2020
Q4 		$49.9M Buy
2,400,000
+250,000
+12% +$4.57M 0.3% 63
2020
Q3 		$46.5M Buy
2,150,000
+650,000
+43% +$15.2M 0.32% 66
2020
Q2 		$35.4M Buy
1,500,000
+875,000
+140% +$16.4M 0.28% 66
2020
Q1 		$7.37M Buy
+625,000
New +$7.97M 0.06% 86

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Thomas Steyer's CYTK Position: Q4 2024 in Review

Thomas Steyer sold out of Cytokinetics (CYTK) in Q4 2024, closing a stake of 102,400 shares — an estimated $5.41M sold.

Thomas Steyer first reported a position in CYTK in Q1 2020 and held it in 19 quarters. The position peaked at $98.9M in Q4 2021. 346 funds tracked by Wall St. Rank hold CYTK as of Q4 2024.

  • Thomas Steyer reported no remaining Cytokinetics position as of Q4 2024 after selling out during the quarter.
  • Thomas Steyer sold 102,400 Cytokinetics shares in Q4 2024, an estimated $5.41M.
  • Thomas Steyer first reported a position in Cytokinetics in Q1 2020 and held it in 19 quarters.
  • Thomas Steyer's Cytokinetics position peaked at $98.9M in Q4 2021.
  • 346 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2024.

Based on Farallon Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.